Jack Nielsen Sells 19,955 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYGet Rating) Director Jack Nielsen sold 19,955 shares of the company’s stock in a transaction dated Tuesday, April 12th. The shares were sold at an average price of $50.05, for a total value of $998,747.75. Following the sale, the director now owns 10,741 shares in the company, valued at approximately $537,587.05. The sale was disclosed in a filing with the SEC, which is available through this link.

Jack Nielsen also recently made the following trade(s):

  • On Thursday, April 14th, Jack Nielsen sold 13,668 shares of Harmony Biosciences stock. The shares were sold at an average price of $52.08, for a total value of $711,829.44.
  • On Thursday, April 7th, Jack Nielsen sold 5,266 shares of Harmony Biosciences stock. The shares were sold at an average price of $50.25, for a total value of $264,616.50.
  • On Monday, April 4th, Jack Nielsen sold 1,027 shares of Harmony Biosciences stock. The stock was sold at an average price of $50.00, for a total value of $51,350.00.
  • On Friday, April 1st, Jack Nielsen sold 2,375 shares of Harmony Biosciences stock. The stock was sold at an average price of $50.00, for a total value of $118,750.00.
  • On Wednesday, March 30th, Jack Nielsen sold 27,851 shares of Harmony Biosciences stock. The stock was sold at an average price of $50.24, for a total value of $1,399,234.24.
  • On Monday, March 28th, Jack Nielsen sold 42,489 shares of Harmony Biosciences stock. The stock was sold at an average price of $50.82, for a total value of $2,159,290.98.
  • On Thursday, March 24th, Jack Nielsen sold 18,935 shares of Harmony Biosciences stock. The stock was sold at an average price of $50.12, for a total value of $949,022.20.
  • On Tuesday, March 22nd, Jack Nielsen sold 6,576 shares of Harmony Biosciences stock. The stock was sold at an average price of $50.13, for a total value of $329,654.88.
  • On Thursday, March 17th, Jack Nielsen sold 5,896 shares of Harmony Biosciences stock. The stock was sold at an average price of $50.05, for a total value of $295,094.80.

Shares of Harmony Biosciences stock opened at $51.54 on Friday. The company has a market cap of $3.04 billion, a PE ratio of 88.86 and a beta of 0.51. Harmony Biosciences Holdings, Inc. has a 52 week low of $25.09 and a 52 week high of $52.75. The business has a 50 day moving average price of $44.58 and a 200-day moving average price of $40.95. The company has a quick ratio of 5.21, a current ratio of 5.29 and a debt-to-equity ratio of 1.02.

Harmony Biosciences (NASDAQ:HRMYGet Rating) last issued its quarterly earnings results on Monday, February 28th. The company reported $0.38 EPS for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.02. Harmony Biosciences had a return on equity of 75.85% and a net margin of 11.33%. During the same quarter in the prior year, the business earned $0.25 earnings per share. As a group, research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 1.56 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Cim LLC purchased a new stake in shares of Harmony Biosciences during the first quarter valued at approximately $341,000. BlackRock Inc. increased its position in shares of Harmony Biosciences by 131.7% during the fourth quarter. BlackRock Inc. now owns 3,739,766 shares of the company’s stock valued at $159,463,000 after acquiring an additional 2,125,593 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Harmony Biosciences by 4.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 11,973 shares of the company’s stock valued at $511,000 after acquiring an additional 500 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Harmony Biosciences by 3.6% during the fourth quarter. California State Teachers Retirement System now owns 27,027 shares of the company’s stock valued at $1,152,000 after acquiring an additional 947 shares during the last quarter. Finally, Parametric Portfolio Associates LLC increased its position in shares of Harmony Biosciences by 215.7% during the fourth quarter. Parametric Portfolio Associates LLC now owns 23,352 shares of the company’s stock valued at $996,000 after acquiring an additional 15,954 shares during the last quarter. 53.82% of the stock is owned by institutional investors.

A number of research firms recently weighed in on HRMY. Zacks Investment Research raised Harmony Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, March 2nd. Cantor Fitzgerald began coverage on Harmony Biosciences in a research note on Thursday. They issued an “overweight” rating and a $63.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $52.60.

About Harmony Biosciences (Get Rating)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Further Reading

Insider Buying and Selling by Quarter for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.